Agilent secures expanded CE Mark for cancer assay

By LabPulse.com staff writers

August 23, 2021 -- Agilent Technologies has received an expanded CE Mark that will allow its PD-L1 IHC 22C3 pharmDx assay -- a companion diagnostic for the Keytruda chemotherapy agent -- to be used for esophageal cancer.

The test may now be used to identify esophageal cancer patients eligible for treatment with Keytruda, a monoclonal antibody developed by Merck that boosts the body's ability to fight cancer cells.

Thomas Scientific inks distribution deal with Agilent
Scientific products distributor Thomas Scientific has signed a strategic distribution deal with Agilent Technologies that will allow Thomas to offer a...
Agilent launches SARS-CoV-2 antibody immunoassay kit
Agilent Technologies has launched a new immunoassay kit for the detection of SARS-CoV-2 antibodies. The kit represents Agilent's entry into the U.S. SARS-CoV-2...
Agilent updates Visiopharm image analysis software
Agilent Technologies has released an updated version of its Visiopharm image analysis software. The software now incorporates HercepTest monoclonal antibody...
FDA approves Agilent assay for lung cancer
The U.S. Food and Drug Administration (FDA) has cleared Agilent Technologies' companion diagnostic assay for use in guiding immunotherapy treatment in...
Agilent launches liquid chromatography-mass spectrometry system in U.S.
Agilent Technologies has announced the U.S. launch of a new liquid chromatography-mass spectrometry system designed to improve diagnostic workflow in...

Copyright © 2021 LabPulse.com

Last Updated np 9/1/2021 12:09:47 PM